Neurological and inflammatory biomarkers in CSF along the Alzheimer's Disease spectrum
Here we present an exploratory study with quantitative immunoassays, where we identified several CSF biomarkers indicative of dementia or progression to dementia covering multiple pathological mechanisms. Further successful integration into a biomarker panel could help personalize treatment, stratify individuals for therapeutic studies and provide a better understanding of how these early pathologies impact disease progression.
Authors
- Martin K. Stengelin (ORCID: https://orcid.org/0000-0002-7298-2213)
- Victòria Fernández (ORCID: https://orcid.org/0000-0002-4809-8196)
- Jacob N. Wohlstadter (ORCID: https://orcid.org/0009-0000-4467-6895)
- Catherine Demos (ORCID: https://orcid.org/0000-0003-3914-1954)
- Xavier Morató (ORCID: https://orcid.org/0000-0002-3012-2864)
- Miyo K. Chatanaka (ORCID: https://orcid.org/0000-0002-5864-8315)
- George B. Sigal (ORCID: https://orcid.org/0000-0001-7149-6400)
- Eleftherios P. Diamandis (ORCID: https://orcid.org/0000-0002-1589-820X)
- Anu Mathew (ORCID: https://orcid.org/0000-0003-3327-3083)
- Jermaine Brown
- Pilar Sánz
- Federico Casales
- Sergi Valero
- Itziar de Rojas
- Josep Blazquez
- Brian Ngo
- Mercè Boada
Institutions
- University of Toronto (CA)
- Instituto de Salud Carlos III (ES)
- Universitat Internacional de Catalunya (ES)
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Sinai Health System (CA)
- Meso Scale Discovery (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_097201
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00